Gilead Sciences 8-K 2010
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Gilead Sciences, Inc.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Item 1.01 Entry into a Material Definitive Agreement.
On April 30, 2010, Gilead Sciences Limited (GSL), a wholly-owned subsidiary of Gilead Sciences, Inc. (Gilead), and Evonik Degussa GmbH, formerly known as Degussa AG (Evonik), entered into an amendment (Amendment) to the Emtricitabine Manufacturing Supply Agreement dated as of June 6, 2006 (Supply Agreement).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.